{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:30:10Z","timestamp":1791282610107,"version":"4.1.0"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T00:00:00Z","timestamp":1423785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s40264-015-0267-y","type":"journal-article","created":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T12:09:36Z","timestamp":1423742976000},"page":"253-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications"],"prefix":"10.1007","volume":"38","author":[{"given":"Geetha","family":"Ramachandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,13]]},"reference":[{"key":"267_CR1","doi-asserted-by":"crossref","DOI":"10.1596\/978-0-8213-8316-2","volume-title":"Global tuberculosis report, 2010","author":"World Health Organisation","year":"2010","unstructured":"World Health Organisation. Global tuberculosis report, 2010. Geneva: WHO; 2010."},{"issue":"8922","key":"267_CR2","first-page":"609","volume":"344","author":"J Crofton","year":"1994","unstructured":"Crofton J. Global challenge of TB. Lancet. 1994;344(8922):609.","journal-title":"Lancet"},{"key":"267_CR3","volume-title":"Guidelines for the management of drug-resistant tuberculosis. WHO\/TB\/96.210 (Rev 1)","author":"J Crofton","year":"1997","unstructured":"Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistant tuberculosis. WHO\/TB\/96.210 (Rev 1). Geneva: WHO; 1997."},{"key":"267_CR4","first-page":"845","volume":"111","author":"W Fox","year":"1975","unstructured":"Fox W, Mitchison DA. Short course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis. 1975;111:845\u20138.","journal-title":"Am Rev Respir Dis"},{"key":"267_CR5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/B978-0-443-06839-3.00035-7","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases","author":"DC Hooper","year":"2010","unstructured":"Hooper DC, Strahilevitz J. Quinolones. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010. p. 487\u2013510.","edition":"7"},{"issue":"1","key":"267_CR6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.mop.0000192520.48411.fa","volume":"18","author":"E Leibovitz","year":"2006","unstructured":"Leibovitz E. The use of fluoroquinolones in children. Curr Opin Pediatr. 2006;18(1):64\u201370.","journal-title":"Curr Opin Pediatr."},{"issue":"1","key":"267_CR7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/AAC.29.1.163","volume":"29","author":"I Hayakawa","year":"1986","unstructured":"Hayakawa I, Atarashi S, Yokohama S, Imamura M, Sakano K, Furukawa M. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother. 1986;29(1):163\u20134.","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"267_CR8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1128\/AAC.36.4.860","volume":"36","author":"KP Fu","year":"1992","unstructured":"Fu KP, Lafredo SC, Foleno B, Isaacson DM, Barrett JF, Tobia AJ, et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992;36(4):860\u20136.","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"267_CR9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1128\/AAC.33.7.1105","volume":"33","author":"HC Neu","year":"1989","unstructured":"Neu HC, Chin NX. In vitro activity of S-Ofloxacin. Antimicrob Agents Chemother. 1989;33(7):1105\u20137.","journal-title":"Antimicrob Agents Chemother."},{"issue":"9","key":"267_CR10","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1128\/AAC.32.9.1336","volume":"32","author":"T Une","year":"1988","unstructured":"Une T, Fujimoto T, Sato K, Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother. 1988;32(9):1336\u201340.","journal-title":"Antimicrob Agents Chemother"},{"key":"267_CR11","doi-asserted-by":"crossref","unstructured":"Moxifloxacin. Tuberculosis (Edinb). 2008;88 (2):127\u2013131.","DOI":"10.1016\/S1472-9792(08)70016-7"},{"issue":"1","key":"267_CR12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-199701000-00036","volume":"16","author":"B Hampel","year":"1997","unstructured":"Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use\u2013safety report. Pediatr Infect Dis J. 1997;16(1):127\u20139 (discussion 60\u20132).","journal-title":"Pediatr Infect Dis J."},{"issue":"5","key":"267_CR13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0962-8479(96)90126-4","volume":"77","author":"WW Yew","year":"1996","unstructured":"Yew WW, Chau CH, Wen KH. Pseudomembranous colitis in a patient treated with ofloxacin for tuberculosis. Tuber Lung Dis. 1996;77(5):484.","journal-title":"Tuber Lung Dis."},{"issue":"9","key":"267_CR14","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/496986","volume":"41","author":"J P\u00e9pin","year":"2005","unstructured":"P\u00e9pin J, Saheb N, Coulombe M-A, Alary M-E, Corriveau M-P, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile\u2013associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254\u201360.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"267_CR15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1473-3099(12)70033-6","volume":"12","author":"D Ettehad","year":"2012","unstructured":"Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(6):449\u201356.","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"267_CR16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2165\/11587280-000000000-00000","volume":"34","author":"AM Tome","year":"2011","unstructured":"Tome AM, Filipe A. Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf. 2011;34(6):465\u201388.","journal-title":"Drug Saf."},{"issue":"10","key":"267_CR17","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.10359","volume":"35","author":"JM Kushner","year":"2001","unstructured":"Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother. 2001;35(10):1194\u20138.","journal-title":"Ann Pharmacother."},{"issue":"5","key":"267_CR18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/11536360-000000000-00000","volume":"33","author":"HH Liu","year":"2010","unstructured":"Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf. 2010;33(5):353\u201369.","journal-title":"Drug Saf."},{"issue":"8","key":"267_CR19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2165\/11534340-000000000-00000","volume":"24","author":"JS Kass","year":"2010","unstructured":"Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs. 2010;24(8):655\u201367.","journal-title":"CNS Drugs."},{"issue":"12","key":"267_CR20","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1177\/106002809703101206","volume":"31","author":"GD Walton","year":"1997","unstructured":"Walton GD, Hon JK, Mulpur TG. Ofloxacin-induced seizure. Ann Pharmacother. 1997;31(12):1475\u20137.","journal-title":"Ann Pharmacother."},{"issue":"5","key":"267_CR21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1345\/aph.1E587","volume":"39","author":"MJ Christie","year":"2005","unstructured":"Christie MJ, Wong K, Ting RH, Tam PY, Sikaneta TG. Generalized seizure and toxic epidermal necrolysis following levofloxacin exposure. Ann Pharmacother. 2005;39(5):953\u20135.","journal-title":"Ann Pharmacother."},{"issue":"10","key":"267_CR22","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00228-009-0717-5","volume":"65","author":"A Bellon","year":"2009","unstructured":"Bellon A, Perez-Garcia G, Coverdale JH, Chacko RC. Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol. 2009;65(10):959\u201362.","journal-title":"Eur J Clin Pharmacol."},{"issue":"4","key":"267_CR23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0387-7604(79)80050-9","volume":"1","author":"M Jo","year":"1979","unstructured":"Jo M, Tachi N, Shinoda M. Convulsions from excessive dosage of nalidixic acid: a case report. Brain Dev. 1979;1(4):327\u20139.","journal-title":"Brain Dev."},{"issue":"192","key":"267_CR24","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/jama.1965.03080250078024","volume":"21","author":"MA Islam","year":"1965","unstructured":"Islam MA, Sreedharan T. Convulsions, hyperglycemia, and glycosuria from overdose of nalidixic acid. JAMA. 1965;21(192):1100\u20131.","journal-title":"JAMA."},{"issue":"6966","key":"267_CR25","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/bmj.309.6966.1411","volume":"309","author":"C Upton","year":"1994","unstructured":"Upton C. Sleep disturbance in children treated with ofloxacin. BMJ. 1994;309(6966):1411.","journal-title":"BMJ."},{"key":"267_CR26","unstructured":"Seddon J, Hesseling A, Finlayson L, Schaaf HS. Toxicity and tolerability of multidrug-resistant tuberculosis preventive treatment in children [abstract no. PC-646-17]. In: 43rd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union): Kuala Lumpur; 2012."},{"issue":"4","key":"267_CR27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijantimicag.2006.11.011","volume":"29","author":"ME Falagas","year":"2007","unstructured":"Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents. 2007;29(4):374\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"267_CR28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.smj.0000197124.31174.7e","volume":"99","author":"AN Makaryus","year":"2006","unstructured":"Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant \u201cclinical\u201d event? South Med J. 2006;99(1):52\u20136.","journal-title":"South Med J."},{"issue":"1","key":"267_CR29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/mol.59.1.122","volume":"59","author":"J Kang","year":"2001","unstructured":"Kang J, Wang L, Chen X-L, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol. 2001;59(1):122\u20136.","journal-title":"Mol Pharmacol."},{"issue":"1","key":"267_CR30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1542-474X.2006.00082.x","volume":"11","author":"JP Tsikouris","year":"2006","unstructured":"Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol. 2006;11(1):52\u20136.","journal-title":"Ann Noninvasive Electrocardiol."},{"issue":"4","key":"267_CR31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0009-9236(03)00009-2","volume":"73","author":"GJ Noel","year":"2003","unstructured":"Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73(4):292\u2013303.","journal-title":"Clin Pharmacol Ther."},{"issue":"5","key":"267_CR32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/0091270004264643","volume":"44","author":"GJ Noel","year":"2004","unstructured":"Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol. 2004;44(5):464\u201373.","journal-title":"J Clin Pharmacol."},{"issue":"12","key":"267_CR33","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1592\/phco.21.20.1468.34482","volume":"21","author":"R Frothingham","year":"2001","unstructured":"Frothingham R. Rates of Torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001;21(12):1468\u201372.","journal-title":"Pharmacotherapy."},{"issue":"11","key":"267_CR34","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/cid\/cis664","volume":"55","author":"F Lapi","year":"2012","unstructured":"Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis. 2012;55(11):1457\u201365.","journal-title":"Clin Infect Dis."},{"issue":"6","key":"267_CR35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1067\/mcp.2000.111482","volume":"68","author":"J-L Demolis","year":"2000","unstructured":"Demolis J-L, Kubitza D, Tenneze L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 and 800\u00a0mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther. 2000;68(6):658\u201366.","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"267_CR36","first-page":"8","volume":"1","author":"LA Osborn","year":"1999","unstructured":"Osborn LA, Skipper B, Arellano I, MacKerrow SD, Crawford MH. Results of resting and ambulatory electrocardiograms in patients with hypothyroidism and after return to euthyroid status. Heart Dis. 1999;1(1):8\u201311.","journal-title":"Heart Dis"},{"issue":"5","key":"267_CR37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000141503","volume":"17","author":"O Bakiner","year":"2008","unstructured":"Bakiner O, Ertorer ME, Haydardedeoglu FE, Bozkirli E, Tutuncu NB, Demirag NG. Subclinical hypothyroidism is characterized by increased QT interval dispersion among women. Med Princ Pract. 2008;17(5):390\u20134.","journal-title":"Med Princ Pract."},{"issue":"7","key":"267_CR38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4158\/EP.13.7.711","volume":"13","author":"O Unal","year":"2007","unstructured":"Unal O, Erturk E, Ozkan H, Kiyici S, Guclu M, Ersoy C, et al. Effect of levothyroxine treatment on QT dispersion in patients with subclinical hypothyroidism. Endocr Pract. 2007;13(7):711\u20135.","journal-title":"Endocr Pract."},{"issue":"1","key":"267_CR39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3346\/jkms.2007.22.1.114","volume":"22","author":"KH Kweon","year":"2007","unstructured":"Kweon KH, Park BH, Cho CG. The effects of l-thyroxine treatment on QT dispersion in primary hypothyroidism. J Korean Med Sci. 2007;22(1):114\u20136.","journal-title":"J Korean Med Sci."},{"issue":"2","key":"267_CR40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5588\/ijtld.11.0074","volume":"16","author":"ME Murphy","year":"2012","unstructured":"Murphy ME, Singh KP, Laurenzi M, Brown M, Gillespie SH. Managing malaria in tuberculosis patients on fluoroquinolone-containing regimens: assessing the risk of QT prolongation. Int J Tuberc Lung Dis. 2012;16(2):144\u20139 (i\u2013iii).","journal-title":"Int J Tuberc Lung Dis."},{"issue":"5","key":"267_CR41","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1086\/516119","volume":"25","author":"JE Burkhardt","year":"1997","unstructured":"Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone-induced arthropathy in animals versus children. Clin Infect Dis. 1997;25(5):1196\u2013204.","journal-title":"Clin Infect Dis."},{"issue":"12","key":"267_CR42","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.inf.0000101994.25947.12","volume":"22","author":"R Grady","year":"2003","unstructured":"Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J. 2003;22(12):1128\u201332.","journal-title":"Pediatr Infect Dis J."},{"issue":"3","key":"267_CR43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.idc.2005.05.005","volume":"19","author":"UB Schaad","year":"2005","unstructured":"Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin N Am. 2005;19(3):617\u201328.","journal-title":"Infect Dis Clin N Am."},{"issue":"4","key":"267_CR44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF01967011","volume":"10","author":"UB Schaad","year":"1991","unstructured":"Schaad UB. Use of quinolones in pediatrics. Eur J Clin Microbiol Infect Dis. 1991;10(4):355\u201360.","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"Suppl 2","key":"267_CR45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-199958002-00008","volume":"58","author":"HS Jafri","year":"1999","unstructured":"Jafri HS, McCracken GH Jr. Fluoroquinolones in paediatrics. Drugs. 1999;58(Suppl 2):43\u20138.","journal-title":"Drugs."},{"issue":"3","key":"267_CR46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1345\/aph.18146","volume":"34","author":"AA Alghasham","year":"2000","unstructured":"Alghasham AA, Nahata MC. Clinical use of fluoroquinolones in children. Ann Pharmacother. 2000;34(3):347\u201359 (quiz 413\u20134).","journal-title":"Ann Pharmacother."},{"issue":"9","key":"267_CR47","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/adc.2010.208843","volume":"96","author":"A Adefurin","year":"2011","unstructured":"Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child. 2011;96(9):874\u201380.","journal-title":"Arch Dis Child."},{"issue":"10","key":"267_CR48","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/INF.0b013e3180cbd382","volume":"26","author":"GJ Noel","year":"2007","unstructured":"Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, et al. Comparative safety profile of levofloxacin in 2,523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J. 2007;26(10):879\u201391.","journal-title":"Pediatr Infect Dis J."},{"issue":"1","key":"267_CR49","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1128\/AAC.00667-09","volume":"54","author":"F Li","year":"2010","unstructured":"Li F, Nandy P, Chien S, Noel GJ, Tornoe CW. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother. 2010;54(1):375\u20139.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"267_CR50","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00006454-200206000-00009","volume":"21","author":"CL Yee","year":"2002","unstructured":"Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J. 2002;21(6):525\u20139.","journal-title":"Pediatr Infect Dis J."},{"key":"267_CR51","unstructured":"Goldman JA, Kearns GL. Fluoroquinolone use in paediatrics: focus on safety and place in therapy. 18th Expert Committee on the Selection and Use of Essential Medicines. World Health Organization; 2011. http:\/\/www.who.int\/selection_medicines\/committees\/expert\/18\/applications\/fluoroquinolone_review.pdf . Accessed 18 Sept 2012."},{"issue":"1","key":"267_CR52","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1542\/peds.2013-3636","volume":"134","author":"JS Bradley","year":"2014","unstructured":"Bradley JS, Kauffman RE, Balis DA, Duffy CM, Gerbino PG, Maldonado SD, Noel GJ. Assessment of musculo-skeletal toxicity five years after therapy with levofloxacin. Paediatr. 2014;134(1):e146\u201353.","journal-title":"Paediatr"},{"issue":"6","key":"267_CR53","first-page":"647","volume":"48","author":"A Tumbanatham","year":"2000","unstructured":"Tumbanatham A, Vinodkumar S. Ofloxacin induced arthropathy in patients with multi-drug resistance tuberculosis. J Assoc Physicians India. 2000;48(6):647\u20138.","journal-title":"J Assoc Physicians India."},{"issue":"11","key":"267_CR54","first-page":"941","volume":"2","author":"VK Arora","year":"1998","unstructured":"Arora VK, Tumbanatham A. Severe arthropathy with ofloxacin in two cases of MDR tuberculosis. Int J Tuberc Lung Dis. 1998;2(11):941\u20133.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"1","key":"267_CR55","first-page":"117","volume":"11","author":"HY Wong","year":"2007","unstructured":"Wong HY, Chau CH, Yew WW. Moxifloxacin-induced arthropathy. Int J Tuberc Lung Dis. 2007;11(1):117.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"12","key":"267_CR56","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1592\/phco.24.17.1807.52348","volume":"24","author":"LV Friedrich","year":"2004","unstructured":"Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy. 2004;24(12):1807\u201312.","journal-title":"Pharmacotherapy."},{"issue":"9","key":"267_CR57","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1046\/j.1440-1746.2001.02570.x","volume":"16","author":"S Saigal","year":"2001","unstructured":"Saigal S, Agarwal SR, Nandeesh HP, Sarin SK. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol. 2001;16(9):1028\u201332.","journal-title":"J Gastroenterol Hepatol."},{"issue":"4","key":"267_CR58","first-page":"173","volume":"12","author":"WW Yew","year":"1992","unstructured":"Yew WW, Lee J, Wong PC, Kwan SY. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. Int J Clin Pharmacol Res. 1992;12(4):173\u20138.","journal-title":"Int J Clin Pharmacol Res."},{"issue":"11","key":"267_CR59","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1086\/598929","volume":"48","author":"CC Ho","year":"2009","unstructured":"Ho CC, Chen YC, Hu FC, Yu CJ, Yang PC, Luh KT. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis. 2009;48(11):1526\u201333.","journal-title":"Clin Infect Dis."},{"issue":"9","key":"267_CR60","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.5588\/ijtld.11.0352","volume":"15","author":"CH Roberts","year":"2011","unstructured":"Roberts CH, Smith C, Breen R, Gadhok R, Murphy M, Aryee A, et al. Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens. Int J Tuberc Lung Dis. 2011;15(9):1275\u20136.","journal-title":"Int J Tuberc Lung Dis."},{"key":"267_CR61","unstructured":"World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. 2008. http:\/\/whqlibdoc.who.int\/publications\/2008\/9789241547581_eng.pdf ."},{"key":"267_CR62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/B978-0-443-06839-3.00026-6","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases","author":"DN Gilbert","year":"2010","unstructured":"Gilbert DN, Leggett JE. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010. p. 359\u201384.","edition":"7"},{"key":"267_CR63","doi-asserted-by":"crossref","unstructured":"Amikacin. Tuberculosis. 2008;88(2):87\u20138.","DOI":"10.1016\/S1472-9792(08)70003-9"},{"key":"267_CR64","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1093\/infdis\/135.Supplement_2.S242","volume":"134","author":"H Kawaguchi","year":"1976","unstructured":"Kawaguchi H. Discovery, chemistry, and activity of amikacin. J Infect Dis. 1976;134:S242\u20138.","journal-title":"J Infect Dis."},{"key":"267_CR65","doi-asserted-by":"crossref","unstructured":"Capreomycin. Tuberculosis (Edinb). 2008;88(2):89\u201391.","DOI":"10.1016\/S1472-9792(08)70004-0"},{"key":"267_CR66","doi-asserted-by":"crossref","unstructured":"Evaluation of a new antituberculous agent. Capreomycin sulfate (capastat sulfate). JAMA. 1973;223(2):179\u201380.","DOI":"10.1001\/jama.1973.03220020045016"},{"issue":"5301","key":"267_CR67","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/231301a0","volume":"231","author":"BW Bycroft","year":"1971","unstructured":"Bycroft BW, Cameron D, Croft LR, Hassanali-Walji A, Johnson AW, Webb T. Total structure of capreomycin IB, a tuberculostatic peptide antibiotic. Nature. 1971;231(5301):301\u20132.","journal-title":"Nature."},{"issue":"5","key":"267_CR68","first-page":"657","volume":"14","author":"N Dauby","year":"2010","unstructured":"Dauby N, Payen MC. Amikacin-induced hypomagnesaemic tetany complicating multidrug-resistant tuberculosis treatment. Int J Tuberc Lung Dis. 2010;14(5):657\u20138.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"2","key":"267_CR69","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bjid.2013.01.007","volume":"17","author":"AC Lemos","year":"2013","unstructured":"Lemos AC, Matos ED. Multidrug\u2013resistant tuberculosis. Braz J Infect Dis. 2013;17(2):239\u201346.","journal-title":"Braz J Infect Dis"},{"issue":"5","key":"267_CR70","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","volume":"43","author":"MP Mingeot-Leclercq","year":"1999","unstructured":"Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003\u201312.","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"267_CR71","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","volume":"43","author":"MJ Rybak","year":"1999","unstructured":"Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549\u201355.","journal-title":"Antimicrob Agents Chemother."},{"issue":"12","key":"267_CR72","first-page":"1314","volume":"11","author":"SS Shin","year":"2007","unstructured":"Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis. 2007;11(12):1314\u201320.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"7","key":"267_CR73","first-page":"622","volume":"6","author":"P Jager de","year":"2002","unstructured":"de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002;6(7):622\u20137.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"3","key":"267_CR74","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1378\/chest.125.3.974","volume":"125","author":"S Shin","year":"2004","unstructured":"Shin S, Furin J, Alcantara F, Hyson A, Joseph K, Sanchez E, et al. Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis. Chest. 2004;125(3):974\u201380.","journal-title":"Chest."},{"issue":"4","key":"267_CR75","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/1097-0142(197704)39:4<1410::AID-CNCR2820390409>3.0.CO;2-D","volume":"39","author":"MJ Keating","year":"1977","unstructured":"Keating MJ, Sethi MR, Bodey GP, Samaan NA. Hypocalcemia with hypoparathyroidism and renal tubular dysfunction associated with aminoglycoside therapy. Cancer. 1977;39(4):1410\u20134.","journal-title":"Cancer."},{"issue":"5","key":"267_CR76","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/thx.25.5.608","volume":"25","author":"AM Holmes","year":"1970","unstructured":"Holmes AM, Hesling CM, Wilson TM. Capreomycin-induced serum electrolyte abnormalities. Thorax. 1970;25(5):608\u201311.","journal-title":"Thorax."},{"issue":"Suppl","key":"267_CR77","first-page":"39","volume":"50","author":"CM Hesling","year":"1969","unstructured":"Hesling CM. Treatment with capreomycin, with special reference to toxic effects. Tubercle. 1969;50(Suppl):39\u201341.","journal-title":"Tubercle."},{"issue":"9728","key":"267_CR78","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/S0140-6736(10)60492-8","volume":"375","author":"K Dheda","year":"2010","unstructured":"Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375(9728):1798\u2013807.","journal-title":"Lancet."},{"key":"267_CR79","doi-asserted-by":"crossref","unstructured":"Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryng. 2011;2011:1\u201319.","DOI":"10.1155\/2011\/937861"},{"key":"267_CR80","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2350-10-2","volume":"10","author":"S Bardien","year":"2009","unstructured":"Bardien S, Human H, Harris T, Hefke G, Veikondis R, Schaaf HS, et al. A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness. BMC Med Genet. 2009;10:2.","journal-title":"BMC Med Genet."},{"issue":"4","key":"267_CR81","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.bbrc.2010.02.075","volume":"393","author":"H Human","year":"2010","unstructured":"Human H, Hagen CM, de Jong G, Harris T, Lombard D, Christiansen M, et al. Investigation of mitochondrial sequence variants associated with aminoglycoside-induced ototoxicity in South African TB patients on aminoglycosides. Biochem Biophys Res Commun. 2010;393(4):751\u20136.","journal-title":"Biochem Biophys Res Commun."},{"issue":"3","key":"267_CR82","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.cr.7310124","volume":"17","author":"G Xing","year":"2007","unstructured":"Xing G, Chen Z, Cao X. Mitochondrial rRNA and tRNA and hearing function. Cell Res. 2007;17(3):227\u201339.","journal-title":"Cell Res."},{"issue":"1","key":"267_CR83","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijantimicag.2010.02.018","volume":"36","author":"EP O\u2019Donnell","year":"2010","unstructured":"O\u2019Donnell EP, Scarsi KK, Scheetz MH, Postelnick MJ, Cullina J, Jain M. Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients. Int J Antimicrob Agents. 2010;36(1):94\u20135.","journal-title":"Int J Antimicrob Agents."},{"issue":"9","key":"267_CR84","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1128\/AAC.31.9.1383","volume":"31","author":"JM Gatell","year":"1987","unstructured":"Gatell JM, Ferran F, Araujo V, Bonet M, Soriano E, Traserra J, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother. 1987;31(9):1383\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5\u20136","key":"267_CR85","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/00016488809119511","volume":"105","author":"P Tran Ba Huy","year":"1988","unstructured":"Tran Ba Huy P, Deffrennes D. Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta Otolaryngol. 1988;105(5\u20136):511\u20135.","journal-title":"Acta Otolaryngol"},{"issue":"5","key":"267_CR86","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00176536","volume":"247","author":"VE Pettorossi","year":"1990","unstructured":"Pettorossi VE, Ferraresi A, Errico P, Draicchio F, Dionisotti S. The impact of different dosing regimens of the aminoglycosides netilmicin and amikacin on vestibulotoxicity in the guinea pig. Eur Arch Otorhinolaryngol. 1990;247(5):277\u201382.","journal-title":"Eur Arch Otorhinolaryngol."},{"issue":"6","key":"267_CR87","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000276162","volume":"52","author":"M Takumida","year":"1990","unstructured":"Takumida M, Nishida I, Nikaido M, Hirakawa K, Harada Y, Bagger-Sjoback D. Effect of dosing schedule on aminoglycoside ototoxicity: comparative cochlear ototoxicity of amikacin and isepamicin. J Otorhinolaryngol Relat Spec. 1990;52(6):341\u20139.","journal-title":"J Otorhinolaryngol Relat Spec."},{"issue":"11","key":"267_CR88","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","volume":"38","author":"CA Peloquin","year":"2004","unstructured":"Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538\u201344.","journal-title":"Clin Infect Dis."},{"issue":"5","key":"267_CR89","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1183\/09031936.00044812","volume":"40","author":"JA Seddon","year":"2012","unstructured":"Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J. 2012;40(5):1277\u201386.","journal-title":"Eur Respir J."},{"issue":"6","key":"267_CR90","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7196\/SAMJ.4964","volume":"102","author":"T Harris","year":"2012","unstructured":"Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J. 2012;102(6):363\u20136.","journal-title":"S Afr Med J."},{"issue":"4","key":"267_CR91","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jinf.2012.09.002","volume":"66","author":"JA Seddon","year":"2013","unstructured":"Seddon JA, Thee S, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in children treated for multidrug-resistant tuberculosis. J Infect. 2013;66(4):320\u20139.","journal-title":"J Infect."},{"issue":"6","key":"267_CR92","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1542\/peds.2005-2235","volume":"117","author":"PC Drobac","year":"2006","unstructured":"Drobac PC, Mukherjee JS, Joseph JK, Mitnick C, Furin JJ, del Castillo H, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics. 2006;117(6):2022\u20139.","journal-title":"Pediatrics."},{"key":"267_CR93","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2334-11-28","volume":"11","author":"L Fairlie","year":"2011","unstructured":"Fairlie L, Beylis NC, Reubenson G, Moore DP, Madhi SA. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis. 2011;11:28.","journal-title":"BMC Infect Dis."},{"issue":"1","key":"267_CR94","first-page":"1","volume":"79","author":"N Rist","year":"1959","unstructured":"Rist N, Grumbach F, Libermann D. Experiments on the antituberculous activity of alpha-ethylthioisonicotinamide. Am Rev Tuberc. 1959;79(1):1\u20135.","journal-title":"Am Rev Tuberc."},{"key":"267_CR95","doi-asserted-by":"crossref","unstructured":"Ethionamide. Tuberculosis. 2008;88(2):106\u20138.","DOI":"10.1016\/S1472-9792(08)70009-X"},{"issue":"1","key":"267_CR96","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1084\/jem.20062100","volume":"204","author":"F Wang","year":"2007","unstructured":"Wang F, Langley R, Gulten G, Dover LG, Besra GS, Jacobs WR Jr, et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007;204(1):73\u20138.","journal-title":"J Exp Med."},{"issue":"5144","key":"267_CR97","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.8284673","volume":"263","author":"A Banerjee","year":"1994","unstructured":"Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994;263(5144):227\u201330.","journal-title":"Science."},{"key":"267_CR98","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0041-3879(65)80058-7","volume":"46","author":"I Kass","year":"1965","unstructured":"Kass I. Chemotherapy regimens used in retreatment of pulmonary tuberculosis. Observations on the efficacy of combinations of kanamycin, ethionamide and either cycloserine or pyrazinamide. Tubercle. 1965;46:151\u201365.","journal-title":"Tubercle."},{"issue":"10","key":"267_CR99","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1164\/rccm.201206-1001CI","volume":"186","author":"JA Seddon","year":"2012","unstructured":"Seddon JA, Furin JJ, Gale M, Del Castillo Barrientos H, Hurtado RM, Amanullah F, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med. 2012;186(10):953\u201364.","journal-title":"Am J Respir Crit Care Med."},{"issue":"9","key":"267_CR100","first-page":"1161","volume":"13","author":"HW Lee","year":"2009","unstructured":"Lee HW, Kim DW, Park JH, Kim SD, Lim MS, Phapale PB, et al. Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2009;13(9):1161\u20136.","journal-title":"Int J Tuberc Lung Dis."},{"key":"267_CR101","doi-asserted-by":"crossref","unstructured":"A comparison of the toxicity of prothionamide and ethionamide: a report from the research committee of the British Tuberculosis Association. Tubercle. 1968;49(2):125\u201335.","DOI":"10.1016\/0041-3879(68)90017-2"},{"key":"267_CR102","doi-asserted-by":"crossref","unstructured":"Comparison of the clinical usefulness of ethionamide and prothionamide in initial treatment of tuberculosis: tenth series of controlled trials. Tubercle. 1968;49(3):281\u201390.","DOI":"10.1016\/0041-3879(68)90048-2"},{"issue":"6","key":"267_CR103","doi-asserted-by":"crossref","first-page":"837","DOI":"10.7326\/0003-4819-100-6-837","volume":"100","author":"D Drucker","year":"1984","unstructured":"Drucker D, Eggo MC, Salit IE, Burrow GN. Ethionamide-induced goitrous hypothyroidism. Ann Intern Med. 1984;100(6):837\u20139.","journal-title":"Ann Intern Med."},{"issue":"4","key":"267_CR104","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1086\/517171","volume":"27","author":"SA Soumakis","year":"1998","unstructured":"Soumakis SA, Berg D, Harris HW. Hypothyroidism in a patient receiving treatment for multidrug-resistant tuberculosis. Clin Infect Dis. 1998;27(4):910\u20131.","journal-title":"Clin Infect Dis."},{"issue":"26","key":"267_CR105","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1056\/NEJM200506303522621","volume":"352","author":"ME McDonnell","year":"2005","unstructured":"McDonnell ME, Braverman LE, Bernardo J. Hypothyroidism due to ethionamide. N Engl J Med. 2005;352(26):2757\u20139.","journal-title":"N Engl J Med."},{"issue":"9","key":"267_CR106","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.5588\/ijtld.10.0707","volume":"15","author":"S Thee","year":"2011","unstructured":"Thee S, Zollner EW, Willemse M, Hesseling AC, Magdorf K, Schaaf HS. Abnormal thyroid function tests in children on ethionamide treatment. Int J Tuberc Lung Dis. 2011;15(9):1191\u20133 (i).","journal-title":"Int J Tuberc Lung Dis."},{"issue":"4","key":"267_CR107","doi-asserted-by":"crossref","first-page":"468","DOI":"10.5588\/ijtld.11.0615","volume":"16","author":"H Satti","year":"2012","unstructured":"Satti H, Mafukidze A, Jooste PL, McLaughlin MM, Farmer PE, Seung KJ. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho. Int J Tuberc Lung Dis. 2012;16(4):468\u201372.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"9","key":"267_CR108","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.5588\/ijtld.12.0305","volume":"16","author":"J Gupta","year":"2012","unstructured":"Gupta J, Breen RAM, Milburn HJ. Drug-induced hypothyroidism in patients receiving treatment for multidrug-resistant tuberculosis in the UK [correspondence]. Int J Tuberc Lung Dis. 2012;16(9):1278.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"11","key":"267_CR109","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.5588\/ijtld.12.0403","volume":"16","author":"C Modongo","year":"2012","unstructured":"Modongo C, Zetola NM. Prevalence of hypothyroidism among MDR-TB patients in Botswana [correspondence]. Int J Tuberc Lung Dis. 2012;16(11):1561\u20132.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"1","key":"267_CR110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.5588\/ijtld.11.0388","volume":"16","author":"BS Dutta","year":"2012","unstructured":"Dutta BS, Hassan G, Waseem Q, Saheer S, Singh A. Ethionamide-induced hypothyroidism. Int J Tuberc Lung Dis. 2012;16(1):141.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"3","key":"267_CR111","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0007-0971(68)80006-3","volume":"62","author":"K Hollinrake","year":"1968","unstructured":"Hollinrake K. Acute hepatic necrosis associated with ethionamide. Br J Dis Chest. 1968;62(3):151\u20134.","journal-title":"Br J Dis Chest."},{"issue":"2","key":"267_CR112","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/0041-3879(72)90030-X","volume":"53","author":"M Swash","year":"1972","unstructured":"Swash M, Roberts AH, Murnaghan DJ. Reversible pellagra-like encephalopathy with ethionamide and cycloserine. Tubercle. 1972;53(2):132\u20136.","journal-title":"Tubercle."},{"issue":"2","key":"267_CR113","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0041-3879(72)90031-1","volume":"53","author":"RK Narang","year":"1972","unstructured":"Narang RK. Acute psychotic reaction probably caused by ethionamide. Tubercle. 1972;53(2):137\u20138.","journal-title":"Tubercle."},{"issue":"6","key":"267_CR114","first-page":"1053","volume":"95","author":"FS Lansdown","year":"1967","unstructured":"Lansdown FS, Beran M, Litwak T. Psychotoxic reaction during ethionamide therapy. Am Rev Respir Dis. 1967;95(6):1053\u20135.","journal-title":"Am Rev Respir Dis."},{"issue":"5","key":"267_CR115","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4103\/0253-7613.100408","volume":"44","author":"PK Sharma","year":"2012","unstructured":"Sharma PK, Bansal R. Gynecomastia caused by ethionamide. Indian J Pharmacol. 2012;44(5):654\u20135.","journal-title":"Indian J Pharmacol."},{"issue":"2","key":"267_CR116","first-page":"196","volume":"3","author":"R Dixit","year":"2012","unstructured":"Dixit R, George J, Sharma AK, Chhabra N, Jangir SK, Mishra V. Ethionamide-induced gynecomastia. J Pharmacol Pharmacother. 2012;3(2):196\u20139.","journal-title":"J Pharmacol Pharmacother."},{"key":"267_CR117","first-page":"439","volume":"17","author":"K Ticholov","year":"1963","unstructured":"Ticholov K, Dobrev P. Severe hypoglycemic manifestations in tuberculous diabetes treated with ethionamide. Tuberkulosearzt. 1963;17:439\u201346.","journal-title":"Tuberkulosearzt."},{"key":"267_CR118","doi-asserted-by":"crossref","unstructured":"Prothionamide. Tuberculosis. 2008;88(2):139\u201340.","DOI":"10.1016\/S1472-9792(08)70020-9"},{"key":"267_CR119","doi-asserted-by":"crossref","unstructured":"Cycloserine. Tuberculosis (Edinb). 2008;88(2):100\u20131.","DOI":"10.1016\/S1472-9792(08)70007-6"},{"issue":"8","key":"267_CR120","doi-asserted-by":"crossref","first-page":"e43467","DOI":"10.1371\/journal.pone.0043467","volume":"7","author":"JM Chen","year":"2012","unstructured":"Chen JM, Uplekar S, Gordon SV, Cole ST. A point mutation in cycA partially contributes to the d-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains. PLoS One. 2012;7(8):e43467.","journal-title":"PLoS One."},{"issue":"1","key":"267_CR121","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/AAC.00558-10","volume":"55","author":"JB Bruning","year":"2011","unstructured":"Bruning JB, Murillo AC, Chacon O, Barletta RG, Sacchettini JC. Structure of the Mycobacterium tuberculosis d-alanine: d-alanine ligase, a target of the antituberculosis drug d-cycloserine. Antimicrob Agents Chemother. 2011;55(1):291\u2013301.","journal-title":"Antimicrob Agents Chemother."},{"issue":"12","key":"267_CR122","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1021\/pr0704332","volume":"6","author":"S Halouska","year":"2007","unstructured":"Halouska S, Chacon O, Fenton RJ, Zinniel DK, Barletta RG, Powers R. Use of NMR metabolomics to analyze the targets of d-cycloserine in mycobacteria: role of d-alanine racemase. J Proteome Res. 2007;6(12):4608\u201314.","journal-title":"J Proteome Res."},{"issue":"1","key":"267_CR123","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000221787","volume":"20","author":"L Zitkova","year":"1974","unstructured":"Zitkova L, Tousek J. Pharmacokinetics of cycloserine and terizidone. A comparative study. Chemotherapy. 1974;20(1):18\u201328.","journal-title":"Chemotherapy."},{"issue":"15","key":"267_CR124","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","volume":"62","author":"CA Peloquin","year":"2002","unstructured":"Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169\u201383.","journal-title":"Drugs."},{"issue":"7","key":"267_CR125","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/j.1468-1331.2008.02171.x","volume":"15","author":"HM Kwon","year":"2008","unstructured":"Kwon HM, Kim HK, Cho J, Hong YH, Nam H. Cycloserine-induced encephalopathy: evidence on brain MRI. Eur J Neurol. 2008;15(7):e60\u20131.","journal-title":"Eur J Neurol."},{"key":"267_CR126","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1378\/chest.36.6.591","volume":"36","author":"CX Holmes","year":"1959","unstructured":"Holmes CX, Martin GE, Fetterhoff KI. The role of the cycloserine (seromycin) blood level in the treatment of pulmonary tuberculosis and the prevention and control of cycloserine (seromycin) toxicity. Dis Chest. 1959;36:591\u20133.","journal-title":"Dis Chest."},{"issue":"5","key":"267_CR127","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","volume":"90","author":"PR Donald","year":"2010","unstructured":"Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb). 2010;90(5):279\u201392.","journal-title":"Tuberculosis (Edinb)."},{"issue":"6","key":"267_CR128","first-page":"749","volume":"8","author":"P Vega","year":"2004","unstructured":"Vega P, Sweetland A, Acha J, Castillo H, Guerra D, Smith Fawzi MC, et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8(6):749\u201359.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"2","key":"267_CR129","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000246533","volume":"191","author":"JH Shim","year":"1995","unstructured":"Shim JH, Kim TY, Kim HO, Kim CW. Cycloserine-induced lichenoid drug eruption. Dermatology. 1995;191(2):142\u20134.","journal-title":"Dermatology."},{"issue":"2","key":"267_CR130","first-page":"187","volume":"1","author":"SK Akula","year":"1997","unstructured":"Akula SK, Aruna AS, Johnson JE, Anderson DS. Cycloserine-induced Stevens-Johnson syndrome in an AIDS patient with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 1997;1(2):187\u201390.","journal-title":"Int J Tuberc Lung Dis."},{"key":"267_CR131","first-page":"267","volume":"58","author":"A Vora","year":"2010","unstructured":"Vora A. Terizidone. J Assoc Physicians India. 2010;58:267\u20138.","journal-title":"J Assoc Physicians India."},{"key":"267_CR132","unstructured":"Weyer K. Annexure 2: DOTS-Plus for multidrug resistant tuberculosis patients in South Africa. Systematic evaluation of a standardised treatment regimen applied under tuberculosis control programme conditions.\u00a02004. http:\/\/www.kznhealth.gov.za\/chrp\/National\/TB?SA TB guidelines 2004.pdf . Accessed 12 Aug 2014."},{"issue":"5","key":"267_CR133","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0025-7125(16)32984-4","volume":"51","author":"M Steiner","year":"1967","unstructured":"Steiner M. Newer and second-line drugs in the treatment of drug-resistant tuberculosis in children. Med Clin N Am. 1967;51(5):1153\u201367.","journal-title":"Med Clin N Am."},{"key":"267_CR134","first-page":"751","volume":"83","author":"B Battaglia","year":"1961","unstructured":"Battaglia B, Kaufman I, Lyons HA, Marsh W. Toxicity of cycloserine combined with isoniazid in the treatment of tuberculosis in children. Am Rev Respir Dis. 1961;83:751\u20132.","journal-title":"Am Rev Respir Dis."},{"key":"267_CR135","first-page":"244","volume":"7","author":"J Schloss","year":"1960","unstructured":"Schloss J, Ismail Z. Cycloserine and isoniazid in childhood tuberculous infections. Antibiotic Med Clin Ther. 1960;7:244\u20138.","journal-title":"Antibiotic Med Clin Ther."},{"issue":"6384","key":"267_CR136","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0140-6736(46)91185-3","volume":"1","author":"J Lehmann","year":"1946","unstructured":"Lehmann J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet. 1946;1(6384):15.","journal-title":"Lancet."},{"key":"267_CR137","doi-asserted-by":"crossref","unstructured":"Para-aminosalicylic acid. Tuberculosis. 2008;88(2):137\u20138.","DOI":"10.1016\/S1472-9792(08)70019-2"},{"issue":"1\u20132","key":"267_CR138","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tube.2003.08.012","volume":"84","author":"C Ratledge","year":"2004","unstructured":"Ratledge C. Iron, mycobacteria and tuberculosis. Tuberculosis (Edinb). 2004;84(1\u20132):110\u201330.","journal-title":"Tuberculosis (Edinb)."},{"key":"267_CR139","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/JB.80.2.225-231.1960","volume":"80","author":"NN Durham","year":"1960","unstructured":"Durham NN, Hubbard JS. Mechanism of competitive inhibition of p-aminobenzoic acid oxidation by p-aminosalicylic acid. J Bacteriol. 1960;80:225\u201331.","journal-title":"J Bacteriol."},{"issue":"Suppl 18","key":"267_CR140","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/1841398a0","volume":"184","author":"NN Durham","year":"1959","unstructured":"Durham NN, Hubbard JS. Antagonism of the oxidative dissimilation of p-aminobenzoic acid by p-aminosalicylic acid. Nature. 1959;184(Suppl 18):1398.","journal-title":"Nature."},{"issue":"6","key":"267_CR141","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1378\/chest.16.6.684","volume":"16","author":"J Lehmann","year":"1949","unstructured":"Lehmann J. The treatment of tuberculosis in Sweden with para-aminosalicylic acid; a review. Dis Chest. 1949;16(6):684\u2013703.","journal-title":"Dis Chest."},{"issue":"4","key":"267_CR142","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0366-0869(57)80137-3","volume":"51","author":"PB Woolley","year":"1957","unstructured":"Woolley PB. The use of antrenyl in gastro-intestinal irritation due to PAS compounds. Br J Tuberc Dis Chest. 1957;51(4):382\u20134.","journal-title":"Br J Tuberc Dis Chest."},{"issue":"3","key":"267_CR143","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1164\/ajrccm.159.3.9807131","volume":"159","author":"CA Peloquin","year":"1999","unstructured":"Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT. Once-daily and twice-daily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med. 1999;159(3):932\u20134.","journal-title":"Am J Respir Crit Care Med."},{"issue":"4800","key":"267_CR144","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/bmj.1.4800.29","volume":"1","author":"RR Hamilton","year":"1953","unstructured":"Hamilton RR. Effect of PAS on the thyroid gland. Br Med J. 1953;1(4800):29\u201330.","journal-title":"Br Med J."},{"issue":"4873","key":"267_CR145","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/bmj.1.4873.1234","volume":"1","author":"JA Balint","year":"1954","unstructured":"Balint JA, Fraser R, Hanno MG. Radio-iodine measurements of thyroid function during and after P.A.S. treatment of tuberculosis. Br Med J. 1954;1(4873):1234\u20137.","journal-title":"Br Med J."},{"issue":"4822","key":"267_CR146","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/bmj.1.4822.1261","volume":"1","author":"HT Davies","year":"1953","unstructured":"Davies HT, Galbraith H-JB. Goitre and hypothyroidism developing during treatment with PAS. BMJ. 1953;1(4822):1261.","journal-title":"BMJ."},{"issue":"4741","key":"267_CR147","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/bmj.2.4741.1193","volume":"2","author":"GM Komrower","year":"1951","unstructured":"Komrower GM. Case of Myxoedema developing during p-aminosalicylic acid therapy. BMJ. 1951;2(4741):1193\u20134.","journal-title":"BMJ."},{"issue":"6845","key":"267_CR148","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0140-6736(54)92552-0","volume":"267","author":"AG Macgregor","year":"1954","unstructured":"Macgregor AG, Somner AR. The anti-thyroid action of para-aminosalicylic acid. Lancet. 1954;267(6845):931\u20136.","journal-title":"Lancet."},{"issue":"4877","key":"267_CR149","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/bmj.1.4877.1494-a","volume":"1","author":"AG Macgregor","year":"1954","unstructured":"Macgregor AG, Somner AR. Iodide in goitre due to P.A.S. BMJ. 1954;1(4877):1494.","journal-title":"BMJ."},{"issue":"6847","key":"267_CR150","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0140-6736(54)90607-8","volume":"267","author":"DA Edwards","year":"1954","unstructured":"Edwards DA, Rowlands EN, Trotter WR. The mechanism of the goitrogenic action of p-aminosalicylic acid. Lancet. 1954;267(6847):1051\u20132.","journal-title":"Lancet."},{"issue":"5","key":"267_CR151","doi-asserted-by":"crossref","first-page":"e37114","DOI":"10.1371\/journal.pone.0037114","volume":"7","author":"H Satti","year":"2012","unstructured":"Satti H, McLaughlin MM, Omotayo DB, Keshavjee S, Becerra MC, Mukherjee JS, et al. Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. PLoS One. 2012;7(5):e37114.","journal-title":"PLoS One."},{"issue":"5","key":"267_CR152","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1542\/peds.21.5.781","volume":"21","author":"N Matsaniotis","year":"1958","unstructured":"Matsaniotis N, Jacobs J, Smith MH. Hypersensitivity reactions associated with sodium para-aminosalicylate therapy; four case reports and review of the literature. Pediatrics. 1958;21(5):781\u201392.","journal-title":"Pediatrics."},{"issue":"2","key":"267_CR153","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/jcp.3.2.114","volume":"3","author":"MJ Lynch","year":"1950","unstructured":"Lynch MJ. Effect of para-amino-salicylic acid on prothrombin time. J Clin Pathol. 1950;3(2):114\u20137.","journal-title":"J Clin Pathol."},{"issue":"10","key":"267_CR154","first-page":"737","volume":"36","author":"QP Ge","year":"2013","unstructured":"Ge QP, Wang QF, Duan HF, Wang J, Chu NH. Clinical analysis of prothionamide and para amino salicylic acid induced hepatotoxicity. Zhonghua Jie He He Hu Xi Za Zhi. 2013;36(10):737\u201340.","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"9297","key":"267_CR155","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(01)06964-1","volume":"358","author":"DJ Diekema","year":"2001","unstructured":"Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet. 2001;358(9297):1975\u201382.","journal-title":"Lancet."},{"issue":"10","key":"267_CR156","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1128\/AAC.41.10.2132","volume":"41","author":"DL Shinabarger","year":"1997","unstructured":"Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother. 1997;41(10):2132\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"267_CR157","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1128\/AAC.41.10.2127","volume":"41","author":"AH Lin","year":"1997","unstructured":"Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother. 1997;41(10):2127\u201331.","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"267_CR158","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/501356","volume":"42","author":"AS Vriese De","year":"2006","unstructured":"De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42(8):1111\u20137.","journal-title":"Clin Infect Dis."},{"issue":"Suppl 1","key":"267_CR159","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","volume":"59","author":"DC Vinh","year":"2009","unstructured":"Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009;59(Suppl 1):S59\u201374.","journal-title":"J Infect."},{"issue":"Suppl 4","key":"267_CR160","first-page":"iv23","volume":"66","author":"S Garazzino","year":"2011","unstructured":"Garazzino S, Tovo PA. Clinical experience with linezolid in infants and children. J Antimicrob Chemother. 2011;66(Suppl 4):iv23\u201341.","journal-title":"J Antimicrob Chemother."},{"issue":"1","key":"267_CR161","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clinthera.2010.01.019","volume":"32","author":"E Chiappini","year":"2010","unstructured":"Chiappini E, Conti C, Galli L, de Martino M. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010;32(1):66\u201388.","journal-title":"Clin Ther."},{"issue":"9 Suppl","key":"267_CR162","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1097\/01.inf.0000087022.58089.d8","volume":"22","author":"L Saiman","year":"2003","unstructured":"Saiman L, Goldfarb J, Kaplan SA, Wible K, Edge-Padbury B, Naberhuis-Stehouwer S, et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J. 2003;22(9 Suppl):S193\u2013200.","journal-title":"Pediatr Infect Dis J."},{"issue":"8","key":"267_CR163","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","volume":"46","author":"SL Gerson","year":"2002","unstructured":"Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723\u20136.","journal-title":"Antimicrob Agents Chemother."},{"issue":"16","key":"267_CR164","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","volume":"367","author":"M Lee","year":"2012","unstructured":"Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508\u201318.","journal-title":"N Engl J Med."},{"issue":"9 Suppl","key":"267_CR165","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1097\/01.inf.0000087021.20838.d9","volume":"22","author":"HC Meissner","year":"2003","unstructured":"Meissner HC, Townsend T, Wenman W, Kaplan SL, Morfin MR, Edge-Padbury B, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J. 2003;22(9 Suppl):S186\u201392.","journal-title":"Pediatr Infect Dis J."},{"issue":"8","key":"267_CR166","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(04)01109-0","volume":"4","author":"AM Bressler","year":"2004","unstructured":"Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis. 2004;4(8):528\u201331.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"267_CR167","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/jac\/dkh405","volume":"54","author":"B Spellberg","year":"2004","unstructured":"Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother. 2004;54(4):832\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"267_CR168","doi-asserted-by":"crossref","first-page":"e1528","DOI":"10.1542\/peds.2010-2125","volume":"127","author":"S Nambiar","year":"2011","unstructured":"Nambiar S, Rellosa N, Wassel RT, Borders-Hemphill V, Bradley JS. Linezolid-associated peripheral and optic neuropathy in children. Pediatrics. 2011;127(6):e1528\u201332.","journal-title":"Pediatrics."},{"issue":"9 Suppl","key":"267_CR169","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1097\/01.inf.0000088671.35064.7c","volume":"22","author":"R Yogev","year":"2003","unstructured":"Yogev R, Patterson LE, Kaplan SL, Adler S, Morfin MR, Martin A, et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J. 2003;22(9 Suppl):S172\u20137.","journal-title":"Pediatr Infect Dis J."},{"issue":"9","key":"267_CR170","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/INF.0b013e3182186035","volume":"30","author":"E Su","year":"2011","unstructured":"Su E, Crowley K, Carcillo JA, Michaels MG. Linezolid and lactic acidosis: a role for lactate monitoring with long-term linezolid use in children. Pediatr Infect Dis J. 2011;30(9):804\u20136.","journal-title":"Pediatr Infect Dis J."},{"issue":"12","key":"267_CR171","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.5588\/ijtld.12.0322","volume":"16","author":"PC Rose","year":"2012","unstructured":"Rose PC, Hallbauer UM, Seddon JA, Hesseling AC, Schaaf HS. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis. 2012;16(12):1588\u201393.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"Suppl 2","key":"267_CR172","first-page":"ii 45","volume":"51","author":"G French","year":"2003","unstructured":"French G. Safety and tolerability of linezolid. J Antimicrob Chemother. 2003;51(Suppl 2):ii 45\u201353.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"267_CR173","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jac\/43.5.615","volume":"43","author":"VM Reddy","year":"1999","unstructured":"Reddy VM, O\u2019Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother. 1999;43(5):615\u201323.","journal-title":"J Antimicrob Chemother."},{"key":"267_CR174","doi-asserted-by":"crossref","unstructured":"Clofazimine. Tuberculosis. 2008;88(2):96\u20139.","DOI":"10.1016\/S1472-9792(08)70006-4"},{"key":"267_CR175","unstructured":"World Health Organization. Chemotherapy of leprosy. Geneva: WHO; 1994. http:\/\/www.who.int\/lep\/resources\/Chemotherapy.pdf . Accessed 10 Jan 2013."},{"issue":"12","key":"267_CR176","doi-asserted-by":"crossref","first-page":"10276","DOI":"10.1074\/jbc.M110.200501","volume":"286","author":"T Yano","year":"2011","unstructured":"Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem. 2011;286(12):10276\u201387.","journal-title":"J Biol Chem."},{"issue":"30","key":"267_CR177","doi-asserted-by":"crossref","first-page":"12147","DOI":"10.1073\/pnas.1203735109","volume":"109","author":"SS Grant","year":"2012","unstructured":"Grant SS, Kaufmann BB, Chand NS, Haseley N, Hung DT. Eradication of bacterial persisters with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci. 2012;109(30):12147\u201352.","journal-title":"Proc Natl Acad Sci."},{"issue":"4 Suppl","key":"267_CR178","first-page":"722","volume":"48","author":"G Ramu","year":"1976","unstructured":"Ramu G, Iyer GG. Side effects of clofazimine therapy. Lepr India. 1976;48(4 Suppl):722\u201331.","journal-title":"Lepr India."},{"issue":"6","key":"267_CR179","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1742-1241.1998.tb08900.x","volume":"52","author":"A Hameed","year":"1998","unstructured":"Hameed A, Beach FX, Kennedy RH, Barry RE. A case of clofazimine enteropathy. Int J Clin Pract. 1998;52(6):439\u201340.","journal-title":"Int J Clin Pract."},{"issue":"1","key":"267_CR180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.47276\/lr.82.1.17","volume":"82","author":"H Singh","year":"2011","unstructured":"Singh H, Nel B, Dey V, Tiwari P, Dulhani N. Adverse effects of multi-drug therapy in leprosy, a two years\u2019 experience (2006\u20132008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur). Lepr Rev. 2011;82(1):17\u201324.","journal-title":"Lepr Rev."},{"issue":"4","key":"267_CR181","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1067\/mpd.2001.111327","volume":"138","author":"M Parizhskaya","year":"2001","unstructured":"Parizhskaya M, Youssef NN, Di Lorenzo C, Goyal RK. Clofazimine enteropathy in a pediatric bone marrow transplant recipient. J Pediatr. 2001;138(4):574\u20136.","journal-title":"J Pediatr."},{"issue":"4 Suppl","key":"267_CR182","first-page":"732","volume":"48","author":"S Balakrishnan","year":"1976","unstructured":"Balakrishnan S, Desikan KV, Ramu G. Quantitative estimation of clofazimine in tissue. Lepr India. 1976;48(4 Suppl):732\u20138.","journal-title":"Lepr India."},{"key":"267_CR183","unstructured":"Revised National Tuberculosis Control Programme. DOTS-Plus guidelines, January 2010. http:\/\/www.tbcindia.nic.in . Accessed 12 Dec 2014."},{"key":"267_CR184","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","volume":"9","author":"EW Orenstein","year":"2009","unstructured":"Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153\u201361.","journal-title":"Lancet Infect Dis"},{"key":"267_CR185","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/S0140-6736(02)08830-X","volume":"359","author":"PG Suarez","year":"2002","unstructured":"Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of a standardized second line drugs treatment for chronic tuberculosis patients: national cohort study in Peru. Lancet. 2002;359:1980\u20139.","journal-title":"Lancet"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-015-0267-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0267-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T11:05:03Z","timestamp":1691233503000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-015-0267-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,13]]},"references-count":185,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1007\/s40264-015-0267-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,13]]}}}